1.03 USD
-0.01 (-0.96%)
BRTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. The financial health of BRTX is average, but there are quite some concerns on its profitability. BRTX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
BRTX had negative earnings in the past year.
BRTX had a negative operating cash flow in the past year.
BRTX had negative earnings in each of the past 5 years.
In the past 5 years BRTX always reported negative operating cash flow.
1.2 Ratios
BRTX has a Return On Assets of -125.92%. This is amonst the worse of the industry: BRTX underperforms 81.09% of its industry peers.
BRTX has a Return On Equity of -221.32%. This is in the lower half of the industry: BRTX underperforms 69.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -125.92% | ||
| ROE | -221.32% | ||
| ROIC | N/A |
ROA(3y)-89.42%
ROA(5y)-144.93%
ROE(3y)-108.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 94.53%, BRTX belongs to the top of the industry, outperforming 94.38% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for BRTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BRTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BRTX has more shares outstanding
BRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -29.84, we must say that BRTX is in the distress zone and has some risk of bankruptcy.
BRTX has a worse Altman-Z score (-29.84) than 88.39% of its industry peers.
There is no outstanding debt for BRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -29.84 |
ROIC/WACCN/A
WACC8.66%
2.3 Liquidity
BRTX has a Current Ratio of 2.07. This indicates that BRTX is financially healthy and has no problem in meeting its short term obligations.
BRTX has a Current ratio of 2.07. This is in the lower half of the industry: BRTX underperforms 74.53% of its industry peers.
BRTX has a Quick Ratio of 2.07. This indicates that BRTX is financially healthy and has no problem in meeting its short term obligations.
BRTX has a Quick ratio of 2.07. This is in the lower half of the industry: BRTX underperforms 72.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.07 | ||
| Quick Ratio | 2.07 |
3. Growth
3.1 Past
BRTX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.17%.
The Revenue has grown by 175.03% in the past year. This is a very strong growth!
The Revenue has been growing by 25.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)4.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.27%
Revenue 1Y (TTM)175.03%
Revenue growth 3Y100.17%
Revenue growth 5Y25.27%
Sales Q2Q%-94.87%
3.2 Future
The Earnings Per Share is expected to grow by 53.21% on average over the next years. This is a very strong growth
Based on estimates for the next years, BRTX will show a very strong growth in Revenue. The Revenue will grow by 210.88% on average per year.
EPS Next Y-38.45%
EPS Next 2Y3.28%
EPS Next 3Y39.42%
EPS Next 5Y53.21%
Revenue Next Year57%
Revenue Next 2Y54.95%
Revenue Next 3Y286.04%
Revenue Next 5Y210.88%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BRTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BRTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BRTX's earnings are expected to grow with 39.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.28%
EPS Next 3Y39.42%
5. Dividend
5.1 Amount
BRTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BRTX (12/2/2025, 11:31:09 AM)
1.03
-0.01 (-0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners8.77%
Inst Owner Change49.41%
Ins Owners24.02%
Ins Owner Change0%
Market Cap9.15M
Revenue(TTM)401.00K
Net Income(TTM)-10.72M
Analysts82.5
Price Target13.26 (1187.38%)
Short Float %2.06%
Short Ratio0.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.23%
Min EPS beat(2)-93.06%
Max EPS beat(2)22.6%
EPS beat(4)3
Avg EPS beat(4)6.92%
Min EPS beat(4)-93.06%
Max EPS beat(4)69.45%
EPS beat(8)7
Avg EPS beat(8)12.9%
EPS beat(12)10
Avg EPS beat(12)12.72%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-53.09%
Min Revenue beat(2)-93.55%
Max Revenue beat(2)-12.63%
Revenue beat(4)0
Avg Revenue beat(4)-57.92%
Min Revenue beat(4)-93.55%
Max Revenue beat(4)-12.63%
Revenue beat(8)4
Avg Revenue beat(8)50.41%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)62.5%
PT rev (3m)62.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)6.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 15.11 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.89 | ||
| P/tB | 2.14 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.47
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0.07
BVpS0.55
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -125.92% | ||
| ROE | -221.32% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.53% | ||
| FCFM | N/A |
ROA(3y)-89.42%
ROA(5y)-144.93%
ROE(3y)-108.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 52.81% | ||
| Cap/Sales | 17.73% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.07 | ||
| Quick Ratio | 2.07 | ||
| Altman-Z | -29.84 |
F-Score4
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)175.34%
Cap/Depr(5y)N/A
Cap/Sales(3y)170.15%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.27%
EPS Next Y-38.45%
EPS Next 2Y3.28%
EPS Next 3Y39.42%
EPS Next 5Y53.21%
Revenue 1Y (TTM)175.03%
Revenue growth 3Y100.17%
Revenue growth 5Y25.27%
Sales Q2Q%-94.87%
Revenue Next Year57%
Revenue Next 2Y54.95%
Revenue Next 3Y286.04%
Revenue Next 5Y210.88%
EBIT growth 1Y-1.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.46%
OCF growth 3YN/A
OCF growth 5YN/A
BIORESTORATIVE THERAPIES INC / BRTX FAQ
Can you provide the ChartMill fundamental rating for BIORESTORATIVE THERAPIES INC?
ChartMill assigns a fundamental rating of 3 / 10 to BRTX.
Can you provide the valuation status for BIORESTORATIVE THERAPIES INC?
ChartMill assigns a valuation rating of 1 / 10 to BIORESTORATIVE THERAPIES INC (BRTX). This can be considered as Overvalued.
What is the profitability of BRTX stock?
BIORESTORATIVE THERAPIES INC (BRTX) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for BRTX stock?
The Earnings per Share (EPS) of BIORESTORATIVE THERAPIES INC (BRTX) is expected to decline by -38.45% in the next year.